Karavilagenin DCAS# 934739-29-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 934739-29-4 | SDF | Download SDF |
PubChem ID | 57330179 | Appearance | Powder |
Formula | C30H46O4 | M.Wt | 470.7 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC(CC=CC(C)(C)O)C1CCC2(C1(CCC34C2C=CC5(C3CCC(C5(C)C)O)OC4=O)C)C | ||
Standard InChIKey | CUJVAMKVNDHSSR-DLGSBZDHSA-N | ||
Standard InChI | InChI=1S/C30H46O4/c1-19(9-8-14-25(2,3)33)20-12-15-28(7)21-13-16-30-22(10-11-23(31)26(30,4)5)29(21,24(32)34-30)18-17-27(20,28)6/h8,13-14,16,19-23,31,33H,9-12,15,17-18H2,1-7H3/b14-8+/t19-,20-,21+,22+,23+,27-,28+,29+,30-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Karavilagenin D exhibits inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as a promoter. 2. Karavilagenin D exhibits inhibition effect against human cancer cell lines. |
Karavilagenin D Dilution Calculator
Karavilagenin D Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1245 mL | 10.6225 mL | 21.245 mL | 42.4899 mL | 53.1124 mL |
5 mM | 0.4249 mL | 2.1245 mL | 4.249 mL | 8.498 mL | 10.6225 mL |
10 mM | 0.2124 mL | 1.0622 mL | 2.1245 mL | 4.249 mL | 5.3112 mL |
50 mM | 0.0425 mL | 0.2124 mL | 0.4249 mL | 0.8498 mL | 1.0622 mL |
100 mM | 0.0212 mL | 0.1062 mL | 0.2124 mL | 0.4249 mL | 0.5311 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cobimetinib (racemate)
Catalog No.:BCC1492
CAS No.:934662-91-6
- Cobimetinib (R-enantiomer)
Catalog No.:BCC1493
CAS No.:934660-94-3
- Cobimetinib
Catalog No.:BCC1491
CAS No.:934660-93-2
- 8-Deacetylyunaconitine
Catalog No.:BCN7609
CAS No.:93460-55-0
- TAK-901
Catalog No.:BCC2180
CAS No.:934541-31-8
- Glucoliquiritin
Catalog No.:BCN6760
CAS No.:93446-18-5
- Conantokin G
Catalog No.:BCC6120
CAS No.:93438-65-4
- ENMD-2076
Catalog No.:BCC2186
CAS No.:934353-76-1
- HSP990 (NVP-HSP990)
Catalog No.:BCC5491
CAS No.:934343-74-5
- GSK1014802(CNV1014802)
Catalog No.:BCC6454
CAS No.:934240-30-9
- A-966492
Catalog No.:BCC2211
CAS No.:934162-61-5
- Venlafaxine
Catalog No.:BCC9190
CAS No.:93413-69-5
- Glimepiride
Catalog No.:BCC2109
CAS No.:93479-97-1
- 2-Iodomelatonin
Catalog No.:BCC6772
CAS No.:93515-00-5
- (4->2)-Abeo-16-hydroxycleroda-2,13-dien-15,16-olide-3-al
Catalog No.:BCN7498
CAS No.:935293-70-2
- TH-237A
Catalog No.:BCC5378
CAS No.:935467-97-3
- Euphorbia factor L7a
Catalog No.:BCN3784
CAS No.:93550-94-8
- MDL 72527
Catalog No.:BCC6060
CAS No.:93565-01-6
- AZD1480
Catalog No.:BCC2191
CAS No.:935666-88-9
- BIX 01294
Catalog No.:BCC1131
CAS No.:935693-62-2
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
- Oprozomib (ONX-0912)
Catalog No.:BCC1146
CAS No.:935888-69-0
- 5-(6-Hydroxybenzofuran-2-yl)-2-(3-methylbut-1-enyl)benzene-1,3-diol
Catalog No.:BCN1304
CAS No.:936006-11-0
- Daphnenone
Catalog No.:BCN3229
CAS No.:936006-13-2
Cucurbitane triterpenoids from the leaves of Momordica charantia, and their cancer chemopreventive effects and cytotoxicities.[Pubmed:22344919]
Chem Biodivers. 2012 Feb;9(2):428-40.
Seventeen cucurbitane-type triterpenoids, 1-17, including six new compounds, (23E)-3beta,25-dihydroxy-7beta-methoxycucurbita-5,23-dien-19-al (1), (23S*)-3beta-hydroxy-7beta,23-dimethoxycucurbita-5,24-dien-19-al (6), (23R*)-23-O-methylmomordicine IV (7), (25xi)-26-hydroxymomordicoside L (8), 25-oxo-27-normomordicoside L (9), and 25-O-methylKaravilagenin D (12), were isolated from a MeOH extract of the leaves of Japanese Momordica charantia. The structures of new compounds were elucidated on the basis of extensive spectroscopic analyses and comparison with literature. Compounds 1-17 were examined for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced with 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, a known primary screening test for inhibitors of tumor promotion. Four compounds, 1, (23E)-3beta,7beta-dihydroxy-25-methoxycucurbita-5,23-dien-19-al (2), Karavilagenin D (11), and 12, showed potent inhibitory effects on EBV-EA induction with IC(50) values in the range of 242-264 mol ratio/32 pmol TPA. In addition, compounds 1 and 11 exhibited inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as a promoter. Furthermore, upon evaluation of the cytotoxic activities of compounds 1-17 against human cancer cell lines, compounds 2, 5-7, 9, and 14 showed potent activities against HL60 cell line, and compound 2 against SK-BR-3 cell line.